Abilify. Buy more. Save more.

The U.S. Food and Drug Administration has approved Abilify (aripiprazole) as an add-on therapy for people with major depressive disorder who don’t benefit enough from antidepressant therapy alone, its makers said Tuesday.
Abilify, approved in November 2002 to treat schizophrenia, is among a class of medications called atypical antipsychotics. The latest approval followed clinical studies involving 743 patients.

Most Popular
3 Questions No Job Seeker Ev…

Bristrol-Myers Squibb (BMS) and Otsuka Pharmaceutical have jointly announced that the US Food and Drug Administration (FDA) approved an additional indication for ABILIFY (aripiprazole) Tablets and Oral Solution, atypical antipsychotics, as of March 1.
With this approval, ABILIFY is now applicable to the maintenance treatm…

Depression and mental illnesses are extremely common in the world that we live in today. In every 5 American adults, at least 1 of them is suffering from either depression or mild mental illness in any given 6 months’ period. However, a point to note…the National Institute of Mental Health reveals t…

The U.S. Food and Drug Administration has approved the Bristol-Myers Squibb antipsychotic drug Abilify (aripiprazole) for adolescents aged 13 to 17 diagnosed with schizophrenia, the company said Tuesday.

Related Results

Some developmentally disabled see benefits from arip…

The U.S. Food and Drug Administration has approved Abilify (aripiprazole) to treat manic and mixed episodes in children aged 10 to 17 with bipolar 1 disorder, makers Otsuka Pharmaceutical Co. and Bristol-Myers Squibb Inc. said Friday.
The drug has been approved for this and other uses in adults for several years.

Most P…

TOKYO — Otsuka Pharmaceutical Co., Ltd. (OPC; Head Office: Chiyoda-ku, Tokyo, Japan; President: Tatsuo Higuchi; Phone: 81-3-3292-0021) announces the launch of an atypical antipsychotic agent, Abilify(R) (development code: OPC-14597, nonproprietary name: aripiprazole), on June 8.
Abilify is an antipsychot…

M2 PRESSWIRE-17 May 2006-US Financial Network: Abbott Enters Agreement with Advanced Life Science Institute and Bristol-Myers Posts Abilify Mania Study(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:17052006 City of Industry, CA - Pharmaceuticals industry alert provided by Equity IR News. Abbott (NYSE:ABT) announced recently it has entered into a licensing agreement with Advanced Life Science Institute, Inc.

…

Abilify is now indicated for patients who suffer from bipolar I disorder with manic and mixed episodes. Bristol-Myers Squibb Co. and Otsuksa …

Most Popular
5 Regular Mistakes In Public Speaking
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Publ…